Sixfold Bioscience completes $10.5M USD seed financing
Funding will support the advancement of Sixfold’s Mergo RNA therapeutics delivery platform, enabling delivery of mRNA and siRNA to tissues beyond the liver
Photo by Christopher Bill on Unsplash
This most recent second close of the seed financing raised $2.2 million USD, bringing the total dilutive and non-dilutive capital raised to $10.5 million USD. Investors in the seed round included Cantos Ventures, Y Combinator, Lombard Street Ventures and Pi Campus, as well as select Angel investors. The Company received further non-dilutive funding from Innovate UK, MedCity, and the European Commission, where the team leads a series of collaborations on RNA therapeutics.
Founded in 2017 by Dr George Foot and Dr Perdrix Rosell, Sixfold develops programmable drug delivery systems, with a current focus on short interfering RNA for gene silencing and messenger RNA for gene expression.Although rapidly expanding within the last couple of years, the RNA therapeutics field is still largely constrained to targeting the liver or local administration. Sixfold’s Mergo platform offers the exciting possibility to expand this promising therapeutic approach to other organs, across several therapeutic indications.
Mergo consists of the RNA therapeutic and biocompatible building blocks that modulate the pharmacokinetic and pharmacodynamic properties of the system to target selected cell types. The building-blocks that form Mergo are computationally screened, assembled using high-throughput chemistry, and then tested, with each iteration feeding into the next. In essence, the Mergo system rapidly learns which is the best combination for delivery to a given tissue.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.